Company profile
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has
- CEO
- Dr. Regina M. Graul Ph.D.
- Headquarters
- Cambridge, MA, United States
- Employees
- 1
- IPO date
- Apr 2, 2019
- Sector
- Healthcare
- Industry
- Biotechnology